TWI774079B - Use of cyclodextrin for manufacturing a composition for inhibiting growth of oral bacteria - Google Patents

Abstract

Use of cyclodextrin for manufacturing a composition for inhibiting growth of oral bacteria is provided in the disclosure, and cyclodextrin is maintained in the oral cavity for a specific time period for inhibiting growth of oral bacteria. The growth of oral bacteria is inhibited by cyclodextrin without the use of high irritating sanitizer and organic solvent, and the formation of antibiotic resistance can be prevented. Use of cyclodextrin for manufacturing a composition for inhibiting plaque, acid etching, calculus or improving gum diseases is further provided in the disclosure.

Description

Use of cyclodextrin for the manufacture of a composition for inhibiting the growth of oral bacteria

The present disclosure relates to the use of cyclodextrins for oral care, and in particular to the use of cyclodextrins to inhibit the growth of oral bacteria.

The oral cavity is a complex and complete microbial ecosystem. The biofilm formed by the interaction between microorganisms, microbial metabolites, and oral cavity and oral secretions provides suitable environment and conditions for the growth and reproduction of various microorganisms. Studies have pointed out that the occurrence of several oral diseases, such as dental caries, calculus, periodontal disease, and gingivitis, are related to the reproduction of harmful bacteria that grow in oral biofilms. If you can inhibit the large growth of harmful bacteria in the mouth, oral diseases can be avoided and improved.

At present, the control of oral harmful bacteria mainly relies on broad-spectrum chemical fungicides, antibiotics and other methods. However, because broad-spectrum chemical fungicides and antibiotics are highly irritating, long-term use will cause a large number of oral bacteria to die or cause bacterial resistance, make oral flora imbalance, and even cause oral cell mutation, causing other diseases. In addition, since broad-spectrum chemical fungicides or antibiotics often require organic solutions (such as alcohol) as solvents, there is a risk of damaging the oral mucosa when used.

Therefore, how to provide an oral bacteriostatic agent that is mild, safe, has bacteriostatic effect and does not produce drug resistance is a problem to be solved.

Some embodiments of the present disclosure provide the use of a cyclodextrin for the manufacture of a composition for inhibiting the growth of oral bacteria, wherein the composition comprises maintenance in the oral cavity for a specified period of time to inhibit the growth of oral bacteria.

In some embodiments, the oral bacteria comprise Streptococcus, Haemophilus, Actinomyces, Lovolella, Escherichia coli, Staphylococcus, or a combination thereof.

In some embodiments, the cyclodextrin includes one or more of alpha-cyclodextrin, beta-cyclodextrin, gamma-cyclodextrin, delta-cyclodextrin, or derivatives thereof.

In some embodiments, the composition is in an oral care implement.

In some embodiments, the weight percent of the cyclodextrin in the oral care article is 0.1% to 1.5%.

In some embodiments, the oral care article comprises a mouthwash, toothpaste, tooth gel, tooth powder, gel, mousse, foam, mouth spray, lozenge, or effervescent tablet.

In some embodiments, the ingredients of oral care products further include surfactants, bactericides, anti-inflammatory agents, hemostatic agents, desensitizers, anti-caries agents, antioxidants, circulation improvers, vitamins, probiotics, probiotic extracts or a combination thereof.

In some embodiments, the ingredients of the oral care product further include thickening agents, chelating agents, buffering agents, humectants, flavoring agents, or combinations thereof.

In some embodiments, inhibiting the growth of oral bacteria comprises inhibiting bacteria in the oral cavity from forming a biofilm.

Also provided in some embodiments of the present disclosure is the use of a cyclodextrin for the manufacture of a composition for inhibiting plaque, acid erosion, calculus, or a combination of the foregoing on a tooth surface, wherein the composition is maintained in the oral cavity for a specific time to inhibit the tooth Surface plaque, acid etching, stones, or a combination of the foregoing.

Some embodiments of the present disclosure further provide the use of a cyclodextrin for the manufacture of a composition for improving gum disease, wherein the composition is maintained in the oral cavity for a specified period of time to improve gum disease, wherein the gum disease comprises gingivitis or periodontal disease inflammation.

The use of the cyclodextrin provided by the present disclosure for inhibiting the growth of oral bacteria can inhibit the growth of bacteria without using bactericides and organic solvents that are highly irritating to body cells. And the taste is mild, which can improve the user's willingness to use. In addition, cyclodextrin also has the property of co-solubilization, which can synergistically enhance the medical efficacy or physiological activity corresponding to other functional active ingredients by raising the upper solubility limit of other functional active ingredients.

In order to make the description of the present invention more detailed and complete, the embodiments and specific embodiments of the present invention are described in detail below; but this is not the only form of implementing or using the specific embodiments of the present invention. The embodiments disclosed below can be combined or substituted with each other under beneficial circumstances, and other embodiments can also be added to one embodiment without further description or description. In the following description, numerous specific details are set forth in detail to enable the reader to fully understand the following embodiments. However, embodiments of the invention may be practiced without these specific details.

As used herein, unless the context specifically defines the article, "a" and "the" can refer to a single one or a plurality. It will be further understood that the words "comprising", "including", "having" and similar words used herein designate the features, regions, integers, steps, operations, elements and/or components recited therein, but do not Other features, regions, integers, steps, operations, elements, components, and/or groups thereof are excluded.

Although a series of operations or steps are used below to illustrate the methods disclosed herein, the order in which these operations or steps are shown should not be construed as a limitation of the present invention. For example, certain operations or steps may be performed in a different order and/or concurrently with other steps. Furthermore, not all operations, steps and/or features must be performed in order to practice embodiments of the present invention. Furthermore, each operation or step described herein may contain several sub-steps or actions.

As used herein, "oral care product" refers to a composition that may include oral care, oral hygiene, or oral appearance for its intended use, or may include administration to the oral cavity for its intended method of use. In some embodiments, the oral care composition is not swallowed, but remains in the oral cavity for a period of time sufficient for the desired use.

As used herein, "biofilm" means the various microbial communities on the tooth or periodontal surface embedded in a polymer matrix of bacterial and saliva origin. The formation of biofilms involves earlier bacterial colonies and interactions between this film. effect. Subsequently, a second colony attaches to the already adherent early colonies (coaggregation) and this process allows the formation of mature biofilms. Inhibition of biofilm growth prevents and reduces bacterial reattachment to tooth or periodontal surfaces.

For example, dental plaque is a biofilm composed of a variety of oral bacteria that adhere to the tooth surface in a three-dimensional structure. The complex structure enables it to contain bacteria with different sensitivities to oxygen. Growth, development and decay in a polymer matrix of matter. Certain bacteria in dental plaque can produce metabolites that erode tooth enamel or gums, causing tooth decay or sensitive teeth, or produce plaque deposits on teeth, leading to calculus... symptoms such as gum disease (such as gingivitis) or periodontitis).

In some embodiments of the present disclosure, the use of a cyclodextrin (CD) for inhibiting oral bacteria is provided, comprising maintaining the cyclodextrin in the oral cavity for a specified time. In some embodiments, oral bacteria include, but are not limited to, Streptococcus , Haemophilus , Actinomyces , Prevotella , Escherichia , or Staphylococcus . In some embodiments, the specified time comprises 0.5 to 10 minutes. In one embodiment, at least 0.5 minutes, 1 minute, 5 minutes, 10 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, or any interval of the foregoing, can achieve oral inhibition effect on bacterial growth. In some embodiments, inhibiting oral bacteria can comprise inhibiting bacteria in the oral cavity from forming a biofilm.

Cyclodextrin is an unsaturated six-membered heterocyclic compound, which is harmless to the human body, has a mild and non-irritating taste, and has the characteristics of amphiphilic molecules with a hydrophobic inner cavity and a hydrophilic shell. The inner cavity can be used as an inclusion body to accommodate a variety of hydrophobic molecules. In the past, it was more common in solubilization, molecular fixation, drug delivery, deodorization and other purposes. It is worth noting that some embodiments of the present disclosure utilize the amphiphilic structural properties of cyclodextrins to coat metabolites produced by oral bacteria and avoid the formation of bacterial biofilms. Cyclodextrins are used for the first time to inhibit the growth of oral cells. grow. In some embodiments, the cyclodextrin includes one or more of α-cyclodextrin, β-cyclodextrin, γ-cyclodextrin, δ-cyclodextrin, or derivatives thereof, and different cyclodextrins have Different hydrophobic molecular coating ability and water solubility, the appropriate cyclodextrin can be selected according to the needs. For example, hydroxypropyl-β-cyclodextrin (HP-β-CD) is modified by β-cyclodextrin, which is not only cheap but also widely available and has excellent water solubility. It can be directly configured with water as mouthwash, which is not only low-cost but also highly convenient to use.

In some embodiments, the composition may be included in an oral care implement. In one embodiment, the weight percent of cyclodextrin in the oral care product is 0.1% to 1.5%, such as 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9 %, 1.0%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, or a weight percent of any of the foregoing spacings. Too high or too low concentration of cyclodextrin cannot achieve the effect of inhibiting the growth of bacteria. If the concentration is too high, some bacteria (such as Klebsiella pneumoniae) will grow. If the concentration is too low, the effect will be ineffective.

In some embodiments, the oral care article comprises a mouthwash, toothpaste, tooth gel, tooth powder, gel, mousse, foam, mouth spray, lozenge, or effervescent tablet. In one embodiment, the oral care composition can be used in non-human mammals such as pets (eg, dogs and cats), as well as humans. In one embodiment, the oral care composition is only suitable for humans.

In some embodiments, the ingredients of the oral care product further include surfactants, functional active ingredients, or both. In one embodiment, the weight percentage of the surfactant in the oral care product is 0.01% to 30%, such as 0.01%, 0.1%, 1%, 5%, 10%, 15%, 30%, or any interval above weight percent. In one embodiment, the weight percent of the functional active ingredient in the oral care device is 0.01 to 10%, such as 0.01%, 0.1%, 1%, 5%, 10%, or any of the foregoing weight percentages.

In one embodiment, the surfactant comprises one or more of an anionic surfactant, a cationic surfactant, a nonionic surfactant, or an amphoteric surfactant.

Functional active ingredients generally refer to ingredients with medical utility or physiological activity, such as bactericides, anti-inflammatory agents, hemostatic agents, desensitizers, anti-caries, antioxidants, circulation improvers, vitamins, probiotics, or probiotics extracts .

In one embodiment, the biocide comprises a cationic biocide, benzoates, iodine species, australin, trichlorodiphenyl ether, and zinc citrate, hydrogen peroxide, halogenated diphenyl ethers (eg, trichlorodiphenyl ethers). Chlorosa), herbal extracts and essential oils (e.g. rosemary extract, tea extract, magnolia extract, thymol, menthol, eucalyptol, geraniol, carvacrol, citral, hinokitiol, catechol, methyl salicylate, epigallocatechin gallate, epigallocatechin, gallic acid, miswak extract, sea buckthorn extract) or a combination thereof.

In one embodiment, the anti-inflammatory agent includes licorice extract (eg, flavonoids in licorice (eg, dipotassium licorice, glycyrrhizin, or glycyrrhetinic acid, etc.)), anti-inflammatory hormones (eg, glucocorticoids), violet Dinghua extract, red peony root, Radix Scrophulariaceae, comfrey, madder, paeonol or combination thereof.

In one embodiment, the hemostatic agent includes tranexamic acid.

In one embodiment, the desensitizing agent comprises one of urea, strontium nitrate, strontium chloride, potassium citrate, stannous fluoride, potassium chloride, grape seed extract, mangosteen extract, apple extract, or variety.

In one embodiment, the anti-caries agent includes fluorides such as stannous fluoride, sodium fluoride, potassium fluoride, sodium monofluorophosphate, sodium fluorosilicate, ammonium fluorosilicate, amine fluorides (eg N' -Octadecyltrienemethyldiamine-N,N,N'-tris(2-ethanol)-hydrogen difluoride), ammonium fluoride, titanium fluoride, hexafluorosulfate, or a combination thereof.

In one embodiment, the antioxidants include vitamins, antioxidant active ingredients in animal and plant extracts, or both.

In one embodiment, the circulation improving agent comprises vitamin E and derivatives thereof, ectoine, plant extracts, or combinations thereof.

It is worth noting that when cyclodextrin is present in oral care products, it can be used as a co-solvent at the same time, for example, to increase the upper limit of solubility of other functional active ingredients, and to improve the situation that the maximum content of functional active ingredients is limited due to limited solubility. That is, in addition to inhibiting the growth of oral bacteria, cyclodextrin also has the synergistic effect of simultaneously raising the upper limit of efficacy of other functional active ingredients.

In some embodiments, the ingredients of oral care products further include excipients (also known as excipients), mainly to enhance the function of functional active ingredients, or to promote dissolution and absorption in the final form to enhance the performance of active ingredients. For example, thickening agents, chelating agents, buffering agents, humectants, flavoring agents, or combinations thereof. In one embodiment, the weight percentage of the adjuvant in the oral care product is 0.02 to 20%, such as 0.02%, 0.1%, 1%, 5%, 10%, 15%, 20% or any of the foregoing weight percentages.

Thickeners are substances that provide desired consistency or stability and enhance the performance of oral care products. In one embodiment, thickeners such as hyaluronic acid, polyvinylpyrrolidone, cellulose, oligosaccharides, glucosylglycerol, carboxyvinyl polymers, carrageenan, hydroxyethyl cellulose (Hydroxyethyl Cellulose; HEC) , natural and synthetic clays (such as aluminum magnesium silicate (VEEGUM) and laponite (such as commercial laponite), water-soluble salts of cellulose ethers (such as Carboxymethyl Cellulose; CMC) and Sodium carboxymethyl hydroxyethyl cellulose), natural gums (such as karaya gum, gum sanctuary, acacia and tragacanth), colloidal magnesium aluminum silicate, silica (such as finely powdered silica), poly Vinylpyrrolidone, carbowaxe, fatty acids and salts thereof, or combinations thereof.

Chelating agents are compounds that can form stable water-soluble complexes with alkaline earth and heavy metal ions. In one embodiment, the chelating agent comprises, for example, edetate.

Buffers can adjust the pH of the oral care composition to, for example, a range of about pH 4.0 to about pH 8.0. In one embodiment, the buffer comprises sodium chloride or sodium fluoride, sodium bicarbonate, sodium phosphate (eg, sodium dihydrogen phosphate (NaH ₂ PO ₄ ), disodium hydrogen phosphate (Na ₂ HPO ₄ ), triphosphate sodium ( _{Na3PO4 )} ), sodium hydroxide, sodium carbonate, sodium acid pyrophosphate, citric acid, sodium citrate and mixtures or combinations thereof.

Moisturizers are ingredients that avoid hardening when oral care products are exposed to air. In one embodiment, a humectant such as glycerin, sorbitol, propylene glycol, or a combination thereof.

Flavoring agents refer to substances that control the mouthfeel or taste of oral care products. In one embodiment, flavoring agents can provide a cooling taste, such as peppermint and its extracts (eg, menthol, peppermint oil), borneol (crystals made from the extraction of branches or leaves of Lauraceae), essential oils, and various flavors One or more of aldehydes, esters (eg, menthyl lactate), or alcohols. Essential oils may include peppermint oil, peppermint oil, wintergreen oil, sassafras oil, clove oil, sage oil, eucalyptus oil, marjoram oil, cinnamon oil, lemon oil, lime oil, grapefruit oil, orange oil or a combination thereof. In one embodiment, the flavoring agent is present in the oral care device at a weight percent of 0.005 to 2 percent, such as 0.005 percent, 0.01 percent, 0.1 percent, 0.15 percent, 0.2 percent, or any of the foregoing weight percent.

In some embodiments of the present disclosure, there is also provided the use of cyclodextrin for the manufacture of a composition that inhibits plaque, acid etching, calculus, or a combination of the foregoing on tooth surfaces, wherein the composition is maintained in the oral cavity for a specified time to inhibit tooth Surface plaque, acid etching, stones, or a combination of the foregoing.

In some embodiments of the present disclosure, there is also provided the use of cyclodextrins for the manufacture of a composition for improving gum disease, wherein the composition is maintained in the oral cavity for a specified period of time to improve gum disease.

To further illustrate the use of the cyclodextrins provided by various embodiments of the present disclosure for inhibiting the growth of oral bacteria, the following implementations are performed. It should be noted that the following embodiments are provided for exemplary purposes only, and are not intended to limit the present invention.

Embodiment 1, the antibacterial test of cyclodextrin

In order to test the inhibitory effect of cyclodextrin on oral bacteria, different concentrations of hydroxypropyl-β-cyclodextrin (including 0.1%, 1%, and 10% by weight) were mixed with Klebsiella pneumoniae. pneumoniae ), Staphylococcus aureus , and Escherichia coli were mixed for a specific time (1 minute and 6 hours), wherein the initial reaction concentration of each group of bacteria was 1×10 ⁵ cfu/mL, and each group of bacteria was detected The number of colonies per unit volume, and the results are plotted as panels 1A to 1C.

The results showed that the groups of 0.1% and 1% hydroxypropyl-β-cyclodextrin could inhibit the growth of bacteria regardless of whether they were used for 1 minute or 6 hours. However, when the concentration was increased to 10%, the growth of L. pneumoniae was promoted instead (47x10 ⁵ cfu/mL). That is, the cyclodextrin needs to be controlled at an appropriate concentration to have the effect of inhibiting the growth of oral bacteria.

Further, the bacteriostatic power (%) of hydroxypropyl-β-cyclodextrin is defined as (the amount of bacteria in the control group-the amount of bacteria in the experimental group)/the amount of bacteria in the control group, and converts from Figure 1A to Figure 1. The bacteriostatic activity of 0.1% and 1% hydroxypropyl-β-cyclodextrin in Figure 1C against each group of bacteria is plotted as Figure 2A and Figure 2B.

The results showed that, in general, 1% hydroxypropyl-β-cyclodextrin had better bacteriostatic activity, and the effect of inhibiting the growth of three kinds of bacteria could be achieved at the same time after acting for 1 minute. In addition, as the working time increases, the bacteriostatic power to some bacteria also increases.

Embodiment 2, the cleaning test of cyclodextrin

In order to test the cleaning effect of removing oral bacteria by using a cleaning solution containing hydroxypropyl-β-cyclodextrin, E. coli and the mixture of mold/yeast were cultured in culture tubes for two days, and then the bacteria solution was discarded. Next, use a cotton swab to smear the wall of the tube, and use a test piece (JNC SK Neofilm ^TW microbiological quick test piece) to detect the amount of bacteria on the cotton swab. The E. coli uses the JNC E. coli/Escherichia coli test piece. (Model #6635) was used to detect mold/yeast, and JNC yeast and mold test strips (Model #6640) were used to detect mold/yeast, and the initial bacterial volume of each group was calculated to be 1×10 ⁴ cfu/mL. Then, pour in the cleaning solution, shake for 1 minute, then pour out the cleaning solution, wherein the cleaning solution includes three groups, which are 1% 25°C cyclodextrin aqueous solution, 65°C reverse osmosis hot water, and 25°C cyclodextrin solution. C of reverse osmosis room temperature water. Next, smear the wall of the tube with a cotton swab again, cultivate the bacteria on the cotton swab for two days, and use the test piece regulated by the Food Law to calculate the amount of bacteria again. The results are shown in Table 1 below.

Table 1. Comparison table of cleaning effect of cyclodextrin cleaning solution bacteria Cyclodextrin aqueous solution 65°C reverse osmosis hot water 25°C reverse osmosis room temperature water Escherichia coli The amount of bacteria after cleaning (cfu/mL) 0 2.0x10 ¹ too much to calculate Inhibition rate(%) 100 99.8 too low to assess Mold/yeast mix The amount of bacteria after cleaning (cfu/mL) 0 0 8.0x10 ¹ Inhibition rate(%) 100 100 99.2%

The results in Table 1 show that using the cyclodextrin aqueous solution as the cleaning solution and simulating the mouthwash process by rinsing the culture tube, the cyclodextrin aqueous solution can achieve better bacteria than reverse osmosis water at 65°C or 25°C. As well as the removal of fungi, it has a better cleaning effect.

Embodiment 3. Mouthwash containing cyclodextrin

In order to further confirm the actual use of oral care products containing cyclodextrin, cyclodextrin was added with natural ingredients to prepare a concentrated mouthwash (the formula contains 47.5% hydroxypropyl-β-cyclodextrin, 3.5% propylene glycol, 3.5 % natural menthol, 1.0% menthyl lactate, 4.5% dipotassium licorice, and water), respectively, conduct stability and diluted use experience questionnaires.

Embodiment three.1, the stability test of concentrated mouthwash

Place the concentrated mouthwash at room temperature/12 months, 30°C/12 months, and 30°C/12 months, and then observe the appearance, smell, content of the concentrated mouthwash and the production of microorganisms (detection). Detect whether fungus, mold, Escherichia coli, Pseudomonas aeruginosa ( Pseudomonas aeruginosa ), or Staphylococcus aureus are produced, wherein the detection limit is 10cfu/g), the results are shown in Table 2.

Table 2. Consolidated Table of Stability Results of Concentrated Mouthwash Storage Conditions room temperature / 12 months 30°C/ 12 months 45°C/ 6 months Exterior Transparent and clear Transparent and clear Transparent and clear colorless colorless very pale yellow smell No abnormality No abnormality No abnormality Content content qualified qualified qualified Microorganisms (lower detection limit <10 cfu/g) none none none

The results show that the concentrated mouthwash can be stored without deterioration for at least 6 months at 45°C, and at least 12 months at room temperature and 30°C.

Example 3.2. Questionnaire on the use of concentrated mouthwash

A total of 13 subjects were asked, after gargling with water, the test group (the concentrated mouthwash of Example 2 was diluted with water to obtain a 1% hydroxypropyl-β-cyclodextrin mouthwash) and the commercially available Rinse the mouth with the product (Listerine Mint Antibacterial Mouthwash), and then fill out a user experience questionnaire. Subjects rated the intensity of the sensation on a scale of 1 to 5. For example, if the irritation score is 5, it means that the irritation is high, and the score is 1, which means the irritation is low; the coolness lasting score is 5, which means the lasting time is long, and the score is 1, which means the lasting time is short; the refreshing feeling score is 5, which means refreshing High sex, a score of 1, indicating low freshness. Next, statistical analysis was used to detect whether there was a significant difference in the average value of the scores between the commercial product and the test product. Finally, the questionnaire results are organized into Tables 3 to 5.

Table 3. The use feeling score of concentrated mouthwash - irritation subject Commercially available test article 1 5 3 2 5 2 3 4 1 4 5 1 5 4 2 6 5 1 7 4 1 8 4 2 9 5 2 10 5 2 11 5 3 12 5 1 13 4 3 average 4.62 1.85 (significantly different from commercially available products)

Table 4. The score of the use of concentrated mouthwash - cooling and lasting subject Commercially available test article 1 3 3 2 4 4 3 4 2 4 2 3 5 3 4 6 3.5 2 7 4 3 8 4 4 9 3 3 10 3 4 11 4 5 12 3 2 13 4 2 average 3.42 3.15 (Not significantly different from the commercially available product)

Table 5. The use feeling score table of concentrated mouthwash - refreshing feeling subject Commercially available test article 1 3 3 2 2 4 3 4 2 4 4 3 5 4 4 6 3 3 7 5 3 8 5 4 9 3 3 10 3 3 11 3 4 12 4 3 13 4 3 average 3.62 3.23 (Not significantly different from the commercially available product)

The results show that there is a significant difference in irritation between the commercial product and the test product, but there is no significant difference in cooling lasting and refreshing feeling. The taste of the test products of the embodiments of the present disclosure is milder and less burdensome than the commercial products.

The use of cyclodextrin for inhibiting the growth of oral bacteria provided by some embodiments of the present disclosure is the first time that cyclodextrin is used as a functional active ingredient for oral health care, without the need to use conventionally highly irritating body cells. Fungicides, which inhibit the growth of bacteria, avoid the formation of biofilms and the risk of bacterial resistance, have excellent removal of bacteria and fungi, and can achieve a minimum of one year without the use of preservatives. Shelf life. In addition, the cyclodextrin has a mild taste and is soluble in water. Therefore, the prepared oral care product is not irritating to the oral mucosa, which can improve the user's willingness to use.

In addition, cyclodextrin also has a synergistic effect with other functional active ingredients. Cyclodextrin can use the co-solubilization properties of amphiphilic molecules on its own structure to increase the upper limit of solubility of functional active ingredients, and further enhance the corresponding medical effects of functional active ingredients or is physiological activity.

Although the present disclosure has been disclosed as above in embodiments, it is not intended to limit the present disclosure. Anyone skilled in the art can make various changes and modifications without departing from the spirit and scope of the present disclosure. The scope of protection of the disclosed contents shall be determined by the scope of the appended patent application.

none

In order to make the above and other objects, features, advantages and embodiments of the present invention more clearly understood, the accompanying drawings are described as follows: Figures 1A-1C illustrate, in Example 1 of the present disclosure, hydroxypropyl-beta-cyclodextrin against Klebsiella pneumoniae (Figure 1A), Staphylococcus aureus (Figure 1B), and Escherichia coli (Fig. 1C) under different action time (1 minute and 6 hours) and different action concentrations (0.1%, 1%, 10%), the comparison diagram of the bacterial count changes per unit volume in each group. Figure 2A illustrates the comparison chart of the bacteriostatic effect of hydroxypropyl-β-cyclodextrin with different weight percentages after hydroxypropyl-β-cyclodextrin acts on oral bacteria for 1 minute in Example 1 of the present disclosure. Figure 2B illustrates the comparison chart of the bacteriostatic effect of hydroxypropyl-β-cyclodextrin with different weight percentages after hydroxypropyl-β-cyclodextrin acts on oral bacteria for 6 hours in Example 1 of the present disclosure.

Domestic storage information (please note in the order of storage institution, date and number) none Foreign deposit information (please note in the order of deposit country, institution, date and number) none

Claims (10)

A use of a cyclodextrin for the manufacture of a composition for inhibiting the growth of oral bacteria, wherein the composition is maintained in the oral cavity for a specific time to inhibit the growth of oral bacteria, wherein the cyclodextrin is hydroxypropyl-β-cyclodextrin, And that specific time is 0.5 minutes to 6 hours. The use of claim 1, wherein the oral bacteria comprises Streptococcus, Haemophilus, Actinomyces, Lavotella, Escherichia coli, Staphylococcus, or a combination thereof. The use of claim 1, wherein the composition is in an oral care product. The use according to claim 3, wherein the weight percentage of the cyclodextrin in the oral care product is 0.1% to 1.5%. The use of claim 3, wherein the oral care product comprises mouthwash, toothpaste, tooth gel, tooth powder, gel, mousse, foam, mouth spray, lozenge, or effervescent tablet. The use according to claim 3, wherein the ingredients of the oral care product further include surfactants, bactericides, anti-inflammatory agents, hemostatic agents, desensitizers, anti-caries agents, antioxidants, circulation improvers, vitamins, probiotics , a probiotic extract or a combination thereof. The use according to claim 3, wherein the components of the oral care product further comprise thickeners, chelating agents, buffering agents, moisturizing agents, flavoring agents or combinations thereof. The use of claim 1, wherein the inhibiting the growth of oral bacteria comprises inhibiting the formation of biofilms by bacteria in the oral cavity. Use of a cyclodextrin for the manufacture of a composition for inhibiting plaque, acid etching, calculus or a combination of the foregoing on tooth surfaces, wherein the composition is maintained in the oral cavity for a specific time to inhibit plaque, acid etching, calculi on tooth surfaces or a combination of the foregoing, wherein the cyclodextrin is hydroxypropyl-beta-cyclodextrin, and the specified time is 0.5 minutes to 6 hours. Use of a cyclodextrin for the manufacture of a composition for improving gum disease, wherein the composition is maintained in the oral cavity for a specific time to improve gum disease, wherein the gum disease comprises gingivitis or periodontitis, wherein the cyclodextrin is a hydroxyl propyl-beta-cyclodextrin, and this specific time is 0.5 minutes to 6 hours.

Images